PTC wins conditional EU Translarna approval
This article was originally published in Scrip
Executive Summary
PTC Therapeutics has been granted conditional approval from the European Commission for its Duchenne muscular dystrophy (DMD) drug Translarna (ataluren), which has yet to produce Phase III data.
You may also be interested in...
EMA Decision Due For Minoryx’s Leriglitazone & Apellis’ Pegcetacoplan
The European Medicines Agency is this week due to decide whether to back pan-EU marketing authorization for five new medicines, including a combination antibiotic product and a drug for chemotherapy-induced neutropenia.
Lebrikizumab Among Nine Drugs To Get EMA Nod; PTC Faces Disappointment For Translarna
The European Medicines Agency has OKd nine new medicines for EU-wide approval, but recommended against renewing the conditional marketing authorization of two drugs.
WuXi eases CAR-T manufacturing burden with new US plant
China's WuXi PharmaTech, an R&D technology company serving the pharmaceutical, biotechnology and medical device industries, has announced construction of a new manufacturing facility in Philadelphia, US designed for cell therapy products, including chimeric antigen receptor T-cell (CAR-T) therapies. More manufacturing power is crucial to the success of this burgeoning, high-potential field.